CN114671802A - 一种高纯度依巴斯汀的制备方法 - Google Patents
一种高纯度依巴斯汀的制备方法 Download PDFInfo
- Publication number
- CN114671802A CN114671802A CN202210392522.5A CN202210392522A CN114671802A CN 114671802 A CN114671802 A CN 114671802A CN 202210392522 A CN202210392522 A CN 202210392522A CN 114671802 A CN114671802 A CN 114671802A
- Authority
- CN
- China
- Prior art keywords
- ebastine
- purity
- acid
- chloro
- washing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229960001971 ebastine Drugs 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 36
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims abstract description 18
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims abstract description 18
- QILSFLSDHQAZET-UHFFFAOYSA-N diphenylmethanol Chemical compound C=1C=CC=CC=1C(O)C1=CC=CC=C1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 4- (1, 1-dimethylethyl) phenyl-4- (4-hydroxy-1-piperidyl) -butanone Chemical compound 0.000 claims abstract description 16
- RLKSQLJFGCDUOX-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-4-chlorobutan-1-one Chemical compound CC(C)(C)C1=CC=C(C(=O)CCCCl)C=C1 RLKSQLJFGCDUOX-UHFFFAOYSA-N 0.000 claims abstract description 13
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012535 impurity Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000007858 starting material Substances 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- 238000005406 washing Methods 0.000 claims description 27
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical group [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000012044 organic layer Substances 0.000 claims description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 6
- 238000007670 refining Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 239000010410 layer Substances 0.000 claims description 5
- 238000004537 pulping Methods 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- OQROAIRCEOBYJA-UHFFFAOYSA-N bromodiphenylmethane Chemical compound C=1C=CC=CC=1C(Br)C1=CC=CC=C1 OQROAIRCEOBYJA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- HUFTWIJFTZKVMR-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-4-(4-hydroxypiperidin-1-yl)butan-1-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(O)CC1 HUFTWIJFTZKVMR-UHFFFAOYSA-N 0.000 description 1
- CIQJWKNJDQKPPO-UHFFFAOYSA-N 1-chloropiperidine Chemical class ClN1CCCCC1 CIQJWKNJDQKPPO-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明提供了一种高纯度依巴斯汀的制备方法,以4‑氯‑1‑(4‑叔丁基苯基)‑1‑丁酮为起始原料,与4‑羟基哌啶缩合得4‑氯‑1‑(4‑(1,1‑二甲基乙基)苯基‑4‑(4‑羟基‑1‑哌啶基)‑丁烷酮),以甲基异丁基甲酮或甲苯为溶剂,加入二苯甲醇,缩合得到依巴斯汀,所得的依巴斯汀,通过成盐进行纯化后游离,所得到的依巴斯汀成品纯度大于99.9%,单杂小于0.1%,符合依巴斯汀药典质量标准。
Description
技术领域
本发明涉及医药化工技术领域,具体而言,涉及一种高纯度依巴斯汀的制备方法。
背景技术
依巴斯汀属于新型氯哌啶类长效、非镇定型第二代组胺H1受体拮抗剂,用于季节性、过敏性鼻炎及慢性特发性荨麻疹等疾患的治疗,具有强效、长效、高选择性的特点,对中枢神经系统的胆碱能受体没有拮抗作用,代谢产物具有更强的抗组胺作用,此外,最近国外研究还表明其具有抗新生血管生成的作用,有望应用于哮喘和气管炎的治疗。
目前已公开的适合工业生产制备依巴斯汀的方法主要有两种:
第一种:4-氯-1-(4-叔丁基苯基)-1-丁酮和4-羟基哌啶缩合生成1-(4-叔丁基苯基)-4-(4-羟基-1-哌啶基)-1-丁酮,再与二苯基溴甲烷缩合生成依巴斯汀。该方法使用的二苯基溴甲烷,为液体,稳定性差,不易保存,毒性较大且成本较高,不利于工业化生产。
第二种:二苯甲醇和4-羟基哌啶缩合生成4-二苯甲氧基哌啶,再与4-氯-1-(4-叔丁基苯基)-1-丁酮缩合生成依巴斯汀。该方法生成的中间体熔点较低,积易氧化,不利于工业化生产中中间体的储存及运输。
发明内容
针对现有技术中存在的不足,本发明所要解决的技术问题是提供一种高纯度依巴斯汀的制备方法,提高产品纯度,降低制备成本,利于工业化生产。
为了解决上述技术问题,本发明采用的技术方案为:
一种高纯度依巴斯汀的制备方法,以4-氯-1-(4-叔丁基苯基)-1-丁酮为起始原料,与4-羟基哌啶催化缩合得4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),再与二苯甲醇缩合得到依巴斯汀;将制得的依巴斯汀成盐,进行纯化处理后游离精制后得到纯度大于99.9%的依巴斯汀。
该制备方法的反应式如下:
所述的高纯度依巴斯汀的制备方法,包括以下步骤:
1)以4-氯-1-(4-叔丁基苯基)-1-丁酮、4-羟基哌啶为原料,在催化剂的条件下,加热回流带水,反应结束后经酸洗碱洗、萃取得到4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮);
2)再加入二苯甲醇在缩合剂的条件下加热回流带水得依巴斯汀;
3)将步骤2)制得的依巴斯汀中加入大分子酸,在甲苯或甲基异丁基甲酮为溶剂中,生成盐析出,离心得到依巴斯汀的盐,用溶剂纯化除杂后,得到高纯度的依巴斯汀盐,然后游离精制得到高纯度的依巴斯汀成品。
所述催化剂选自碘化钾,碘化亚铜。
所述的缩合剂选自对甲苯磺酸,硫酸;其摩尔用量为所述二苯甲醇摩尔量的0.5~1倍,优选为0.7~0.9倍。
所述大分子酸选自硫酸,磷酸,草酸,马来酸,富马酸和对甲苯磺酸,优选为马来酸,富马酸;其摩尔用量为所述依巴斯汀的1-1.5倍,优选为1.2~1.5倍。
所述的高纯度依巴斯汀的制备方法,用于纯化的有机溶剂选自甲苯,甲基异丁基甲酮,二甲苯,氯苯,二氯甲烷。
所述的高纯度依巴斯汀的制备方法,用于精制的溶剂选自乙醇,甲醇,异丙醇。
所述的高纯度依巴斯汀的制备方法,缩合反应回流的时间为4—6h。
所述的高纯度依巴斯汀的制备方法,成盐的反应时间为1-2h。
所述的高纯度依巴斯汀的制备方法,步骤如下:
1)将4-氯-1-(4-叔丁基苯基)-1-丁酮加入甲苯溶液中,分别加入4-羟基哌啶,碳酸氢钠和碘化钾,升温至回流反应完全,降温至室温,用饱和食盐水水洗一次,3N的盐酸萃取后,水层用氢氧化钠调至pH值10-11,用乙酸乙酯萃取后,有机层蒸干,加入正己烷,离心甩料得4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮);
2)取4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),甲苯磺酸,甲基异丁基甲酮升温至回流,滴加二苯甲醇的甲基异丁基甲酮溶液,滴完后继续反应至完全;
3)饱和盐水洗涤一次,10%的氢氧化钠洗涤一次,3N的盐酸洗涤一次后,加入富马酸,升温至回流反应,降温离心甩滤,固体用甲苯打浆两次,固体加入甲酮,10%氢氧化钠室温搅拌,分层,有机层有水洗次后,拉干,加入乙醇,重结晶后,降温至-5-5℃,烘干后得到高纯度依巴斯汀。
所得的依巴斯汀盐通过碱游离后,用甲醇,乙醇,异丙醇中的一种,所得的依巴斯汀成品纯度大于99.9%,单杂小于0.1%,符合依巴斯汀药典质量标准。
有益效果:与现有技术相比,本发明的优势在于:
本发明提供的高纯度依巴斯汀的制备方法,以4-氯-1-(4-叔丁基苯基)-1-丁酮为起始原料,与4-羟基哌啶缩合得4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),继续加入二苯甲醇,缩合后得到依巴斯汀,然后将所得的依巴斯汀,通过成盐进行纯化除杂精制后游离,得到的依巴斯汀成品纯度大于99.9%,单杂小于0.1%,符合依巴斯汀药典质量标准。是一种新的依巴斯汀的制备和纯化方法,具有很好的工业化前景。
附图说明
图1是实施例1产品HPLC图;
图2是实施例2产品HPLC图;
图3是实施例3产品HPLC图;
具体实施方式
下面结合实施例对本申请做进一步说明。
以下实施例中,产品纯度的检测方法为高效液相方法,主要检测仪器为赛默飞ULtiMate3000。检测方法为:流动相:乙腈:磷酸盐缓冲液=70:30;色谱柱:用十八烷基硅烷键合硅胶为填充剂(Water Xbridge C18 250mm*4.6mm,5um或效能相当)。检测波长:210nm,柱温:25℃,流速:1.0ml/min,进样量:20ul。
实施例1
一种依巴斯汀的制备及纯化方法,包括以下步骤:
1)将20kg 4-氯-1-(4-叔丁基苯基)-1-丁酮加入90kg甲苯溶液中,分别加入4-羟基哌啶8.0kg,14.2kg碳酸氢钠和2.0kg碘化钾,升温至回流反应10h,降温至室温,用40kg饱和食盐水水洗一次,40kg 3N的盐酸萃取后,水层用10%的氢氧化钠调至pH值10-11,用54kg乙酸乙酯萃取后,有机层蒸干,加入正己烷26kg,离心甩料得19.6kg 4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮)。
2)将19.6kg 4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),甲苯磺酸13.5kg,甲基异丁基甲酮59kg升温至回流,滴加23.4kg二苯甲醇的甲基异丁基甲酮溶液,滴完后继续反应5h,饱和盐水洗涤一次,10%的氢氧化钠洗涤一次,3N的盐酸洗涤一次后,加入11.2kg的富马酸,升温至回流反应1h,降温离心甩滤,固体用(125kg×2)甲苯打浆两次,固体加入67kg甲酮,10%氢氧化钠室温搅拌1h后,分层,有机层有水洗3次后,拉干,加入112kg乙醇,重结晶后,降温至-5-5℃,烘干后得到11.5kg依巴斯汀。
对产品进行检测,结果如图1所示,纯度大于99.9%,单杂小于0.1%。
实施例2
一种依巴斯汀的制备及纯化方法,包括以下步骤:
1)将20kg 4-氯-1-(4-叔丁基苯基)-1-丁酮加入95kg甲基异丁基甲酮溶液中,分别加入4-羟基哌啶8.0kg,14.2kg碳酸氢钠和2.0kg碘化钾,升温至回流反应10h,降温至室温,用40kg饱和食盐水水洗一次,40kg 3N的盐酸萃取后,水层用10%的氢氧化钠调至pH值10-11,用54kg乙酸乙酯萃取后,有机层蒸干,加入正己烷26kg,离心甩料得20.2kg 4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮)。
2)将20.2kg 4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),对甲苯磺酸14.1kg,甲基异丁基甲酮59kg升温至回流,滴加25.3kg二苯甲醇的甲基异丁基甲酮溶液,滴完后继续反应5h,饱和盐水洗涤一次,10%的氢氧化钠洗涤一次,3N的盐酸洗涤一次后,加入11.7kg的马来酸,升温至回流反应1h,降温离心甩滤,固体用(130kg×2)甲基异丁基甲酮打浆两次,固体加入70kg甲酮,10%氢氧化钠室温搅拌1h后,分层,有机层有水洗3次后,拉干,加入118kg甲醇,重结晶后,降温至-5-5℃,烘干后得到11.2kg依巴斯汀。
对产品进行检测,结果如图2所示,纯度大于99.9%,单杂小于0.1%。
实施例3
一种依巴斯汀的制备及纯化方法,包括以下步骤:
1)将20kg 4-氯-1-(4-叔丁基苯基)-1-丁酮加入90kg甲苯溶液中,分别加入4-羟基哌啶8.0kg,14.2kg碳酸氢钠和2.0kg碘化钾,升温至回流反应10h,降温至室温,用40kg饱和食盐水水洗一次,40kg 3N的盐酸萃取后,水层用10%的氢氧化钠调至pH值10-11,用54kg乙酸乙酯萃取后,有机层蒸干,加入正己烷26kg,离心甩料得20.0kg 4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮)。
2)将4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮)20.kg,对甲苯磺酸14.0kg,甲基异丁基甲酮59kg升温至回流,滴加25.0kg二苯甲醇的甲基异丁基甲酮溶液,滴完后继续反应5h,饱和盐水洗涤一次,10%的氢氧化钠洗涤一次,3N的盐酸洗涤一次后,加入10.0kg的磷酸,升温至回流反应1h,降温离心甩滤,固体用(100kg×2)甲基异丁基甲酮打浆两次,固体加入70kg甲酮,10%氢氧化钠室温搅拌1h后,分层,有机层有水洗3次后,拉干,加入120kg异丙醇,重结晶后,降温至-5-5℃,烘干后得到10.5kg依巴斯汀。
对产品进行检测,结果如图3所示,纯度大于99.9%,单杂小于0.1%。
Claims (10)
1.一种高纯度依巴斯汀的制备方法,其特征在于:以4-氯-1-(4-叔丁基苯基)-1-丁酮为起始原料,与4-羟基哌啶催化缩合得4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),再与二苯甲醇缩合得到依巴斯汀;将制得的依巴斯汀成盐,进行纯化处理后游离精制后得到纯度大于99.9%的依巴斯汀。
2.根据权利要求1所述的高纯度依巴斯汀的制备方法,其特征在于,包括以下步骤:
1)以4-氯-1-(4-叔丁基苯基)-1-丁酮、4-羟基哌啶为原料,在催化剂的条件下,加热回流带水,反应结束后经酸洗碱洗、萃取得到4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮);
2)再加入二苯甲醇在缩合剂的条件下加热回流带水得依巴斯汀;
3)将步骤2)制得的依巴斯汀中加入大分子酸,在甲苯或甲基异丁基甲酮为溶剂中,生成盐析出,离心得到依巴斯汀的盐,用溶剂纯化除杂后,得到高纯度的依巴斯汀盐,然后游离精制得到高纯度的依巴斯汀成品。
3.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:所述催化剂选自碘化钾,碘化亚铜。
4.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:所述的缩合剂选自对甲苯磺酸,硫酸;其摩尔用量为所述二苯甲醇摩尔量的0.5~1倍。
5.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:所述大分子酸选自硫酸,磷酸,草酸,马来酸,富马酸和对甲苯磺酸;其摩尔用量为所述依巴斯汀的1-1.5倍。
6.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:用于纯化的有机溶剂选自甲苯,甲基异丁基甲酮,二甲苯,氯苯,二氯甲烷。
7.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:用于精制的溶剂选自乙醇,甲醇,异丙醇。
8.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:缩合反应回流的时间为4-6h。
9.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:成盐的反应时间为1-2h。
10.根据权利要求2所述的高纯度依巴斯汀的制备方法,其特征在于:
1)将4-氯-1-(4-叔丁基苯基)-1-丁酮加入甲苯溶液中,分别加入4-羟基哌啶,碳酸氢钠和碘化钾,升温至回流反应完全,降温至室温,用饱和食盐水水洗一次,3N的盐酸萃取后,水层用氢氧化钠调至pH值10-11,用乙酸乙酯萃取后,有机层蒸干,加入正己烷,离心甩料得4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮);
2)取4-氯-1-(4-(1,1-二甲基乙基)苯基-4-(4-羟基-1-哌啶基)-丁烷酮),甲苯磺酸,甲基异丁基甲酮升温至回流,滴加二苯甲醇的甲基异丁基甲酮溶液,滴完后继续反应至完全;
3)饱和盐水洗涤一次,10%的氢氧化钠洗涤一次,3N的盐酸洗涤一次后,加入富马酸,升温至回流反应,降温离心甩滤,固体用甲苯打浆两次,固体加入甲酮,10%氢氧化钠室温搅拌,分层,有机层有水洗次后,拉干,加入乙醇,重结晶后,降温至-5-5℃,烘干后得到高纯度依巴斯汀。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210392522.5A CN114671802B (zh) | 2022-04-14 | 2022-04-14 | 一种高纯度依巴斯汀的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210392522.5A CN114671802B (zh) | 2022-04-14 | 2022-04-14 | 一种高纯度依巴斯汀的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114671802A true CN114671802A (zh) | 2022-06-28 |
CN114671802B CN114671802B (zh) | 2024-05-17 |
Family
ID=82078955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210392522.5A Active CN114671802B (zh) | 2022-04-14 | 2022-04-14 | 一种高纯度依巴斯汀的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114671802B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6201124B1 (en) * | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
CN1887866A (zh) * | 2006-07-21 | 2007-01-03 | 杭州保灵有限公司 | 一种依巴斯汀的制备方法 |
WO2009157006A1 (en) * | 2008-06-26 | 2009-12-30 | Micro Labs Limited | Process of preparing ebastine |
WO2011121099A2 (en) * | 2010-04-01 | 2011-10-06 | Arevipharma Gmbh | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
CN102260206A (zh) * | 2011-06-10 | 2011-11-30 | 南通大学 | 一种光稳定剂1-苄基-2,2,6,6-四甲基-4-羟基哌啶的制备方法 |
WO2018042305A1 (en) * | 2016-08-29 | 2018-03-08 | Symed Labs Limited | Improved processes for preparation of bilastine using novel intermediates |
CN109593058A (zh) * | 2019-01-23 | 2019-04-09 | 江苏联环药业股份有限公司 | 一种依巴斯汀的制备方法 |
CN114014796A (zh) * | 2021-11-16 | 2022-02-08 | 江苏联环药业股份有限公司 | 一类依巴斯汀的盐及其制备方法和应用 |
-
2022
- 2022-04-14 CN CN202210392522.5A patent/CN114671802B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6201124B1 (en) * | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
CN1887866A (zh) * | 2006-07-21 | 2007-01-03 | 杭州保灵有限公司 | 一种依巴斯汀的制备方法 |
WO2009157006A1 (en) * | 2008-06-26 | 2009-12-30 | Micro Labs Limited | Process of preparing ebastine |
WO2011121099A2 (en) * | 2010-04-01 | 2011-10-06 | Arevipharma Gmbh | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
CN102260206A (zh) * | 2011-06-10 | 2011-11-30 | 南通大学 | 一种光稳定剂1-苄基-2,2,6,6-四甲基-4-羟基哌啶的制备方法 |
WO2018042305A1 (en) * | 2016-08-29 | 2018-03-08 | Symed Labs Limited | Improved processes for preparation of bilastine using novel intermediates |
CN109593058A (zh) * | 2019-01-23 | 2019-04-09 | 江苏联环药业股份有限公司 | 一种依巴斯汀的制备方法 |
CN114014796A (zh) * | 2021-11-16 | 2022-02-08 | 江苏联环药业股份有限公司 | 一类依巴斯汀的盐及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
ZHOUJIE YU ET AL.: "Synthesis of [2H5]-ebastine fumarate and [2H5]-hydroxyebastine", 《J. LABEL COMPD. RADIOPHARM》, vol. 54, 31 December 2010 (2010-12-31), pages 352 - 356 * |
ZHOUJIE YU ET AL.: "Synthesis of [2H5]-ebastine fumarate and [2H5]-hydroxyebastine", 《J. LABEL COMPD. RADIOPHARM》, vol. 54, pages 352 - 356 * |
张敉主编: "《褐煤蜡》", 冶金工业出版社, pages: 77 - 79 * |
虞舟杰;田磊;陈礼勤;: "羟基依巴斯汀的合成方法研究", 中国药物化学杂志, no. 01, 20 February 2011 (2011-02-20), pages 40 - 43 * |
Also Published As
Publication number | Publication date |
---|---|
CN114671802B (zh) | 2024-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101107242B (zh) | 阿立哌唑的盐 | |
CN102617359B (zh) | 一种制备盐酸溴己新的方法 | |
CN112876454A (zh) | 一种人工合成(r,s)-尼古丁盐的制备方法 | |
WO2011161690A1 (en) | Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof | |
EP1412341B1 (en) | Process for the preparation of racemic citalopram and/or s- or r-citalopram by separation of a mixture of r- and s-citalopram | |
CN101367759B (zh) | 一种高纯度苯磺酸氨氯地平的合成方法 | |
CN110372609B (zh) | 一种噁拉戈利钠盐的纯化方法 | |
CN111793026A (zh) | 一种硫酸羟氯喹及其对映体的晶型和制备方法 | |
JP2005507900A (ja) | シタロプラムの製造方法 | |
JP2011516519A (ja) | アルガトロバン一水和物の多形体及びその合成方法 | |
CN101316820A (zh) | 制备手性氨氯地平龙胆酸盐的方法 | |
CN114671802A (zh) | 一种高纯度依巴斯汀的制备方法 | |
CN109988083B (zh) | 高光学纯度草酸艾司西酞普兰中间体s构型二醇的制备方法 | |
NO309035B1 (no) | Ny fremgangsmÕte for fremstilling av ropivacainhydrokloridmonohydrat | |
CN106866625B (zh) | 酮色林的制备方法 | |
CN112679508B (zh) | 一种托法替布中间体的制备方法 | |
CN115403509A (zh) | 一种雷芬那辛中间体的制备方法 | |
CN114085152A (zh) | 一种制备2-(4-硝基苯基)丁酸的方法 | |
CN114195739A (zh) | 高纯度盐酸罗沙替丁醋酸酯及其中间体和它们的制备方法 | |
CN112645901A (zh) | 一种1-环己基哌嗪的制备方法 | |
CN115677579B (zh) | 四氢罂粟碱及其中间体的制备方法 | |
CN111303066A (zh) | 阿瑞匹坦杂质的制备方法 | |
CN114907262B (zh) | 一种合成5′-甲氧基劳丹素的方法 | |
CN111302996A (zh) | 一种高手性纯度的富马酸氯马斯汀的制备方法 | |
CN110734393A (zh) | N-苄基-3-氧代哌啶-4-羧酸乙酯盐酸盐的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |